摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

7-(nitromethyl)-1,4-dioxaspiro[4.5]decane | 29897-29-8

中文名称
——
中文别名
——
英文名称
7-(nitromethyl)-1,4-dioxaspiro[4.5]decane
英文别名
spiro<(3-nitromethylcyclohexane)-1,2'-dioxolane>;3-Nitromethyl-cyclohexanon-aethylenketal;7-(Nitromethyl)-1,4-dioxaspiro[4.5]decane
7-(nitromethyl)-1,4-dioxaspiro[4.5]decane化学式
CAS
29897-29-8
化学式
C9H15NO4
mdl
——
分子量
201.222
InChiKey
ABJZYRJMWWASNF-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.9
  • 重原子数:
    14
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    64.3
  • 氢给体数:
    0
  • 氢受体数:
    4

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    7-(nitromethyl)-1,4-dioxaspiro[4.5]decane 在 lithium aluminium tetrahydride 作用下, 以 四氢呋喃 为溶剂, 以71%的产率得到spiro<(3-aminomethylcyclohexane)-1,2'-dioxolane>
    参考文献:
    名称:
    亚二氢吲哚,吲哚和吲哚,二十一吗啉相关化合物的吲哚方法
    摘要:
    吲哚15的亚硝酸脱氨基用作制备吗啡类似物1b的新策略中的关键反应。
    DOI:
    10.1016/s0040-4039(00)85512-4
  • 作为产物:
    描述:
    2-环己烯-1-酮四丁基氟化铵silica gel 作用下, 以 四氢呋喃 为溶剂, 反应 1.0h, 生成 7-(nitromethyl)-1,4-dioxaspiro[4.5]decane
    参考文献:
    名称:
    亚二氢吲哚,吲哚和吲哚,二十一吗啉相关化合物的吲哚方法
    摘要:
    吲哚15的亚硝酸脱氨基用作制备吗啡类似物1b的新策略中的关键反应。
    DOI:
    10.1016/s0040-4039(00)85512-4
点击查看最新优质反应信息

文献信息

  • Indole as a tool in synthesis. Indolenine approach to 4,5-epoxy-10-normorphinans
    作者:Janos Sapi、Seloua Dridi、Jacqueline Laronze、Françoise Sigaut、Dominique Patigny、Jean-Yves Laronze、Jean Lévy、Loïc Toupet
    DOI:10.1016/0040-4020(96)00378-x
    日期:1996.6
    B-ring were synthesized using the “nitrous acid deamination” of indolenines as the key step. Thus, indolenines 13 and 15 were prepared by Fischer synthesis from the corresponding bicyclic ketolactams 6 and 12, respectively, and further transformed into the related hexahydrodibenzofurans. Ketolactam 6 was obtained from 3-nitromethylcyclohexanone using classical chemistry, whereas 12 was built up by fragmentation
    吲哚烯酮的“亚硝酸基”为关键步骤合成了特征在于缺乏B环的吗啡骨架的4,5-环氧-10去甲吗啡喃2a和2b。因此,通过费歇尔合成法分别从相应的双环酮内酰胺6和12制备吲哚啉13和15,并将其进一步转化为相关的六氢二苯并呋喃。酮内酰胺6是使用传统化学方法从3-硝基甲基环己酮中获得的,而12通过使全氢pin庚酮断裂,然后进行分子内Diels-Alder环化作用来形成“环糊精”。虽然该过程导致了不自然的环连接(2b),但通过碱催化4,5-环氧17-甲基-9-氧代-10-nor-14α-吗啡喃21的差向异构化获得了自然构型(2a)。
  • An Acidic Layered Clay Is Combined with A Basic Layered Clay for One-Pot Sequential Reactions
    作者:Ken Motokura、Noriaki Fujita、Kohsuke Mori、Tomoo Mizugaki、Kohki Ebitani、Kiyotomi Kaneda
    DOI:10.1021/ja052386p
    日期:2005.7.13
    A Ti4+-exchanged montmorillonite (Ti4+-mont) and a hydrotalcite (HT) are strong solid Brønsted acid and base, and these two clay catalysts could be used in a single reactor without neutralization of active sites. Because the Ti4+-mont have active acid site in the narrow interlayers, the base sites of large HT particles show no interaction with the acid sites. A variety of acid and base reactions, such as esterification, acetalization, deacetalization, aldol reaction, Michael reaction, and epoxidation, proceeded using both the Ti4+-mont and the HT in a single reactor.
  • TRPV4 ANTAGONISTS
    申请人:GlaxoSmithKline Intellectual Property (No. 2) Limited
    公开号:EP2720697B1
    公开(公告)日:2016-07-20
  • US8927585B2
    申请人:——
    公开号:US8927585B2
    公开(公告)日:2015-01-06
  • [EN] TRPV4 ANTAGONISTS<br/>[FR] ANTAGONISTES DE TRPV4
    申请人:GLAXOSMITHKLINE LLC
    公开号:WO2012174340A1
    公开(公告)日:2012-12-20
    The present invention relates to spirocarbamate analogs, pharmaceutical compositions containing them and their use as TRPV4 antagonists. The TRPV4 antagonist may be administered alone or in conjunction with one or more other therapeutic agents, ego agents being selected from the group consisting of endothelin receptor antagonists, angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists, vasopeptidase inhibitors, vasopressin receptor modulators, diuretics, digoxin, beta blocker, aldosterone antagonists, iontropes, NSAIDS, nitric oxide donors, calcium channel modulators, muscarinic antagonists, steroidal anti-inflammatory drugs, bronchodilators, anti-histamines, leukotriene antagonist, HMG-CoA reductase inhibitors, dual non-selective padrenoceptor and u1 -adrenoceptor antagonists, type-5 phosphodiesterase inhibitors, and renin inhibitors.
查看更多